We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-17.79%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.33B
AUM Growth
-$491M
(-27%)
Cap. Flow
-$49.3M
Cap. Flow
% of AUM
-3.7%
Top 10 Holdings %
Top 10 Hldgs %
64.77%
Holding
54
New
6
Increased
6
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$18.2M |
| 2 |
Pliant Therapeutics
PLRX
|
+$18.2M |
| 3 |
GH Research
GHRS
|
+$15.8M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
+$14.7M |
| 5 |
BridgeBio Pharma
BBIO
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$20.2M |
| 2 |
Vaxcyte
PCVX
|
+$20M |
| 3 |
ACLX
Arcellx
ACLX
|
+$16.9M |
| 4 |
ArriVent BioPharma
AVBP
|
+$15.6M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$14.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Corbus Pharmaceuticals
CRBP
$190M
| $12.6M | 0.95% |
2,375,000
| – | – |
|
|
RNAM
27
DELISTED
Avidity Biosciences
RNAM
| $11.8M | 0.89% |
400,000
-650,000
| -62% | -$20.2M |
|
|
MTSR
28
DELISTED
Metsera Inc
MTSR
| $10.9M | 0.82% |
+400,000
| New | +$11.3M |
|
29
enGene Therapeutics
ENGN
$121M
| $10.4M | 0.78% |
2,323,595
| – | – |
|
|
BIOA
30
BioAge Labs
BIOA
$538M
| $9.89M | 0.74% |
2,629,529
| – | – |
|
31
Rhythm Pharmaceuticals
RYTM
$7.96B
| $7.95M | 0.6% |
150,000
-250,000
| -63% | -$13.9M |
|
|
OKUR
32
OnKure Therapeutics
OKUR
$168M
| $7.9M | 0.59% |
1,837,739
| – | – |
|
33
Biomea Fusion
BMEA
$91.3M
| $7.61M | 0.57% |
3,570,872
| – | – |
|
34
Korro Bio
KRRO
$195M
| $6.62M | 0.5% |
+380,303
| New | +$11.3M |
|
|
35
Vaxcyte
PCVX
$8.64B
| $6.61M | 0.5% |
175,000
-250,000
| -59% | -$20M |
|
|
AARD
36
Aardvark Therapeutics
AARD
$173M
| $6.01M | 0.45% |
+800,189
| New | +$8.98M |
|
|
MBX
37
MBX Biosciences
MBX
$3.27B
| $5.17M | 0.39% |
700,000
| – | – |
|
38
CALL
NewAmsterdam Pharma
NAMS
$3.34B
| $5.12M | 0.38% |
+250,000
| New | +$5.56M |
|
39
Enliven Therapeutics
ELVN
$4.43B
| $4.92M | 0.37% |
250,000
| – | – |
|
40
CALL
Janux Therapeutics
JANX
$967M
| $4.05M | 0.3% |
+150,000
| New | +$5.65M |
|
|
41
Pliant Therapeutics
PLRX
$65M
| $4.05M | 0.3% |
+3,000,000
| New | +$18.2M |
|
42
KALA BIO
KALA
$14.5M
| $3.46M | 0.26% |
12,061
| – | – |
|
43
Stoke Therapeutics
STOK
$2.11B
| $1.69M | 0.13% |
254,161
| – | – |
|
44
Biohaven
BHVN
$2.21B
| $240K | 0.02% |
10,000
-45,539
| -82% | -$1.61M |
|
45
ImmunityBio
IBRX
$8.1B
| – | – |
-3,000,000
| Closed | -$7.68M |
|
46
Omeros
OMER
$959M
| – | – |
-300,000
| Closed | -$2.96M |
|
|
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-25,000
| Closed | -$316K |
|
48
UroGen Pharma
URGN
$2.29B
| – | – |
-300,000
| Closed | -$3.19M |
|
|
VERV
49
DELISTED
Verve Therapeutics
VERV
| – | – |
-350,000
| Closed | -$1.97M |
|
|
YARW
50
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
| – | – |
-27,887
| Closed | -$4.67M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Cormorant Asset Management held 54 positions worth $1.33B, down 27% from $1.82B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Cormorant Asset Management withdrew a net $49.3M in Q1 2025, closing 10 positions and reducing 13 holdings. Its most notable exit was ArriVent BioPharma, an estimated $15.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Pliant Therapeutics worth $4.05M.
- Cormorant Asset Management's largest Q1 2025 buy was Pliant Therapeutics: 3,000,000 shares worth $4.05M.
- Cormorant Asset Management added most to Edgewise Therapeutics in Q1 2025, an estimated $18.2M increase.
- Cormorant Asset Management's biggest Q1 2025 reduction was Avidity Biosciences, cutting an estimated $20.2M.
- Cormorant Asset Management fully exited ArriVent BioPharma in Q1 2025, selling an estimated $15.6M.
- Cormorant Asset Management's ten largest holdings make up 65% of its $1.33B portfolio in Q1 2025.
- Cormorant Asset Management opened 6 new positions and closed 10 in Q1 2025.
- Cormorant Asset Management's portfolio value fell 27% quarter-over-quarter to $1.33B.
Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.